Amgen

This study tests whether a new drug, ABP 206, works as well as the approved drug OPDIVO (nivolumab) for people with advanced melanoma that cannot be removed by surgery or has spread. About 633 adults who have not had prior treatment for their advanced melanoma will receive either…

This study tests an investigational drug called dazodalibep in 651 adults with Sjögren's syndrome who have moderate-to-severe disease activity. The goal is to see if the drug can reduce overall disease activity and improve symptoms like dryness, compared to a placebo. Participant…

This study tests a drug called sotorasib in people with advanced solid tumors that have a specific genetic change (KRAS G12C). The main goals are to check safety and find the best dose. About 713 adults with various advanced cancers, including lung cancer, are taking part. The dr…

This early-phase study tests a new drug called AMG 355, given alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumor…

This study tests a drug called sotorasib, alone or with other cancer treatments, in adults with advanced solid tumors that have a specific KRAS G12C gene change. The main goals are to check safety and how well the drug works at shrinking or controlling tumors. About 610 participa…

This study tests a drug called inebilizumab in 238 adults with myasthenia gravis, a disease that causes muscle weakness. The goal is to see if it improves daily activities like talking, swallowing, and moving. Participants receive either the drug or a placebo, and results are mea…

This study tests an experimental drug called tarlatamab in 222 adults with small cell lung cancer that has come back or not responded to at least two prior treatments. The main goals are to see if the drug shrinks tumors and to check its safety. Participants receive tarlatamab at…

This study compares a new drug, ABP 234, to the standard treatment Keytruda for people with advanced or metastatic non-squamous non-small cell lung cancer who have not had prior treatment. About 315 participants will receive either ABP 234 or Keytruda to see if the new drug works…

This study tests whether the drug tarlatamab can delay cancer growth and extend life in people with limited-stage small cell lung cancer who have completed chemotherapy and radiation. About 404 adults will receive either tarlatamab or a placebo. The goal is to see if tarlatamab h…

This study tests a drug called inebilizumab to see if it can prevent flare-ups in people with IgG4-related disease, a rare condition that causes swelling and damage in multiple organs. About 135 adults who have had recent flare-ups will receive either the drug or a placebo. The m…

This phase 3 study compares a new drug, tarlatamab, with standard treatments in 509 adults whose small cell lung cancer has returned after initial chemotherapy. The main goal is to see if tarlatamab helps people live longer. Participants must have measurable disease and have prog…

This study tests a drug called blinatumomab in Chinese children (ages 1 month to 18 years) whose B-cell acute lymphoblastic leukemia has come back or not responded to standard treatment. The main goal is to see how many children achieve complete remission. The study also monitors…

This early-stage study tests a combination of three drugs (tarlatamab, YL201, and an anti-PD-L1) in about 200 adults with extensive stage small cell lung cancer that has worsened after initial treatment. The main goal is to check safety and side effects, while also measuring how …

This study compares a new drug, AMG 510, to a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific mutation called KRAS G12C. About 345 adults whose cancer has already been treated but has worsened are taking part. The main goal…

This study tests a new drug called anvumetostat, alone or with chemotherapy (docetaxel), in adults whose advanced solid tumors lack a gene called MTAP. The goal is to find safe doses and see if the drug shrinks tumors. About 329 people will take part across multiple phases.

This study tests a new medicine called maridebart cafraglutide to see if it helps control blood sugar in adults with type 2 diabetes. About 409 people will receive either the drug or a placebo for 24 weeks. Researchers will measure changes in blood sugar levels and body weight.

This early-phase study tests a new drug called tarlatamab combined with standard chemotherapy and immunotherapy for people with extensive stage small cell lung cancer. The main goal is to check safety and side effects, while also measuring how well the tumors respond. About 184 a…

This study tests a drug called tarlatamab in 32 Chinese adults with advanced small cell lung cancer that has worsened after at least two prior treatments. The goal is to see if the drug can shrink tumors and help control the disease. Participants receive the drug and are monitore…

This early-phase study tests a new treatment called AMG 119 for adults with small cell lung cancer that has returned or not responded to standard chemotherapy. The treatment uses specially engineered immune cells (CAR T cells) to attack the cancer. The main goals are to check saf…

This large Phase 3 study tests whether the drug olpasiran can prevent heart attacks, heart-related death, or urgent procedures in people with high levels of lipoprotein(a) — a genetic risk factor — and existing heart disease. About 7,300 participants receive either olpasiran or a…

This study is testing a new drug called bemarituzumab combined with other cancer treatments for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink tumors. About 72 adul…

This study tests the drug XGEVA (denosumab) in Chinese adults and teens aged 12 and older with giant cell tumor of bone, a rare but serious bone growth. The goal is to see if the drug can shrink tumors or stop them from getting worse. Participants receive XGEVA and are monitored …

This study looks at how well the drug Prolia works and how safe it is for Chinese men with osteoporosis. About 102 men aged 30 to 90 with low bone density or a history of fractures will receive Prolia injections. The main goal is to see if bone density in the lower spine improves…

This study tests whether adding the drug bemarituzumab to standard chemotherapy and immunotherapy (nivolumab) helps people with advanced stomach or gastroesophageal junction cancer live longer. The trial includes about 515 adults whose tumors have a specific protein called FGFR2b…

This early-stage study tests the safety and tolerability of tarlatamab in about 269 adults with small cell lung cancer that has come back or not responded to standard platinum-based chemotherapy. The main goal is to find the best dose and check for side effects. This is not a cur…

This study tests a drug called apremilast in Japanese children aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if it can clear or nearly clear their skin by week 16. Participants must have tried topical treatments without success and be candidates for st…

This study looks at the long-term safety of inebilizumab, a drug for neuromyelitis optica spectrum disorder (NMOSD). It measures how the drug affects immune cells and antibody levels over time, and what happens when treatment stops. The study involves 32 adults who have already b…

This study tests a new medication called maridebart cafraglutide for weight loss in 279 Japanese adults with obesity. Participants receive either the drug or a placebo for 72 weeks. The main goals are to see how much weight they lose and if at least 5% of body weight is lost. Thi…

This study tests whether giving evolocumab (a cholesterol-lowering drug) very early after a heart attack, along with usual care, can reduce the risk of another heart attack, stroke, artery-clearing procedures, or death. About 6,000 adults hospitalized for a heart attack are parti…

This study tests a new medication called maridebart cafraglutide to help adults with obesity or overweight lose weight. About 3853 participants will receive either the drug or a placebo for 72 weeks. The main goal is to see how much body weight changes from the start of the study…

This study tests an experimental drug called rocatinlimab in 317 adults with moderate-to-severe asthma. The goal is to see if it can reduce the number of asthma attacks. Participants continue their usual asthma medications while receiving the drug or a placebo.

This study tests a new drug called xaluritamig in about 50 men whose prostate cancer has returned after surgery or radiation but has not spread. The main goal is to check the drug's safety and side effects. Researchers will also measure how well it controls PSA levels, a marker o…

This study tests an injected drug called teprotumumab in people with moderate-to-severe active thyroid eye disease, a condition that causes eye bulging and discomfort. About 89 adults will receive either the drug or a placebo to see if it reduces eye bulging by at least 2 mm with…

This study tests an experimental drug called HZN-1116 in 209 adults with Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. Participants receive either the drug or a placebo to see if it reduces disease activity and improves symptoms like pain. The goal is …

This study compares a new drug, ABP 234, to the standard immunotherapy Keytruda in people with early-stage non-squamous non-small cell lung cancer. Participants have already had surgery and chemotherapy. The goal is to see if ABP 234 works similarly in the body, not to cure the d…

This study tests whether adding tarlatamab to durvalumab helps people with extensive-stage small-cell lung cancer live longer than durvalumab alone. About 563 adults who finished initial chemotherapy and durvalumab without their cancer getting worse will take part. The main goal …

This study tests different doses of tarlatamab in about 252 adults with small cell lung cancer that has worsened after standard chemotherapy. The goal is to see how well the drug shrinks tumors and controls the disease. Participants receive tarlatamab infusions and are monitored …

This study tests whether adding the drug bemarituzumab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. The trial includes about 547 adults whose tumors have high levels of a protein called FGFR2b. Participants receive e…

This study is testing whether a new injectable medication called maridebart cafraglutide helps adults with type 2 diabetes lose weight. Over 1,100 participants who are overweight or have obesity will receive either the drug or a placebo for 72 weeks. The main goal is to see if th…

This study is testing the long-term safety and effectiveness of an experimental drug called rocatinlimab for people with moderate-to-severe eczema. It involves over 2,600 adults and adolescents who previously participated in earlier rocatinlimab studies. The research aims to see …

This study tests whether the drug erenumab can prevent migraines in children (ages 6 to under 12) and adolescents (12 to under 18) who have episodic migraines. About 457 participants will receive either erenumab or a placebo. The main goal is to see if the drug reduces the number…

This study tests a drug called romiplostim in people with lung, ovarian, or breast cancer who have low platelets from chemotherapy. Low platelets can force doctors to delay or reduce chemo doses. The goal is to see if romiplostim helps patients get their full chemo on schedule. A…

This study looks at how safe the drug apremilast is for children aged 6 to 17 with mild to moderate plaque psoriasis. About 51 kids will take the drug and be monitored for side effects, growth, and development. The goal is to make sure the treatment is safe for younger patients.

This study tests a drug called rocatinlimab in adults with prurigo nodularis, a skin condition causing intense itching and bumps. Participants have not gotten enough relief from creams or ointments. The goal is to see if the drug reduces itching and clears skin lesions over 24 we…

This study tests an experimental drug called dazodalibep in 434 adults with moderate-to-severe Sjögren's syndrome, a condition causing dry eyes, dry mouth, and fatigue. Participants receive either the drug or a placebo to see if it improves symptoms and quality of life. The goal …

This early-stage study tests how two different injection forms of the drug maridebart cafraglutide are processed by the body in 349 adults with overweight or obesity. Participants receive a single dose, and researchers measure drug levels and side effects. The goal is to compare …

This early-stage study tests how the body processes two different injection forms of maridebart cafraglutide, an experimental drug for overweight or obesity. About 348 adults aged 18-60 with a BMI between 25 and 40 will receive a single dose and be monitored for drug levels and s…

This early-stage study tests whether maridebart cafraglutide, a potential weight-loss drug, affects the heart's electrical activity. About 81 adults with overweight or obesity will receive the drug, a placebo, or a positive control to measure changes in heart rhythm. The goal is …